Be Biopharma

Be Biopharma (Be Bio) is a Cambridge, Massachusetts clinical-stage biotechnology company founded in October 2020 by Longwood Fund together with B cell engineering researchers David Rawlings, M.D. and Richard James, Ph.D. of Seattle Children's Research Institute. The company develops engineered B Cell Medicines (BCMs) — a patient's own B cells engineered to produce a therapeutic protein — for genetic disease, cancer and other serious conditions. Its lead candidate, BE-101, inserted a functional Factor IX gene into primary human B cells for hemophilia B and held FDA Orphan Drug and Fast Track designations; a second program, BE-102, targeted hypophosphatasia. The company raised $82M in October 2024 and $92M in a January 2025 Series C, dosed the first participant in the Phase 1/2 BeCoMe-9 trial in July 2025, and terminated that trial in June 2026 for stated strategic business reasons. Be Biopharma is a therapeutics developer, not a software company: it has never published a developer program, API, SDK or machine-readable contract.

Be Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Cell Therapy, and Gene Therapy.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyLife SciencesCell TherapyGene TherapyPharmaceuticalsHealthcareClinical TrialsRare Disease

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.6 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/be-biopharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

LinkedIn

Other 2

Properties that don't map to a standard resource type

Archive

Source (apis.yml)

aid: be-biopharma
name: Be Biopharma
description: 'Be Biopharma (Be Bio) is a Cambridge, Massachusetts clinical-stage biotechnology company founded in October
  2020 by Longwood Fund together with B cell engineering researchers David Rawlings, M.D. and Richard James, Ph.D. of Seattle
  Children''s Research Institute. The company develops engineered B Cell Medicines (BCMs) — a patient''s own B cells engineered
  to produce a therapeutic protein — for genetic disease, cancer and other serious conditions. Its lead candidate, BE-101,
  inserted a functional Factor IX gene into primary human B cells for hemophilia B and held FDA Orphan Drug and Fast Track
  designations; a second program, BE-102, targeted hypophosphatasia. The company raised $82M in October 2024 and $92M in a
  January 2025 Series C, dosed the first participant in the Phase 1/2 BeCoMe-9 trial in July 2025, and terminated that trial
  in June 2026 for stated strategic business reasons. Be Biopharma is a therapeutics developer, not a software company: it
  has never published a developer program, API, SDK or machine-readable contract.'
url: https://raw.githubusercontent.com/api-evangelist/be-biopharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Life Sciences
- Cell Therapy
- Gene Therapy
- Pharmaceuticals
- Healthcare
- Clinical Trials
- Rare Disease
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/be-biopharma-domain-security.yml
- type: LLMsTxt
  url: llms/be-biopharma-llms.txt
- type: Website
  url: https://be.bio/
- type: Archive
  url: https://web.archive.org/web/20260513184102/https://be.bio/
- type: LinkedIn
  url: https://www.linkedin.com/company/be-biopharma-inc
- type: SecondaryMarket
  url: https://forgeglobal.com/be-biopharma_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: defunct
  detail: Be Biopharma's own domain be.bio no longer resolves — its authoritative nameservers (ns1.g02.cfdns.net) return SOA
    only for both the apex and www, so there is no host left to probe; the site was last archived 2026-05-13, the company
    terminated its lead BeCoMe-9 hemophilia B trial in June 2026, and LinkedIn now lists a single employee.
  evidence:
  - url: https://be.bio/
    status: 0
  - url: https://www.be.bio/.well-known/security.txt
    status: 404
  - url: https://www.be.bio/.well-known/openid-configuration
    status: 404
  - url: https://www.be.bio/.well-known/ai-plugin.json
    status: 404
  - url: https://web.archive.org/web/20260513184102/https://be.bio/
    status: 200
  - url: https://api.github.com/search/users?q=bebiopharma+OR+be-biopharma
    status: 200
  checked: '2026-08-06'